Biota receives US$231 million BARDA contract to advance laninamivir development

Download PDF Copy

Apr 1 2011

Biota Holdings Limited (ASX:BTA) advises that the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) has awarded up to an estimated US$231 million contract to its wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of laninamivir. The contract is fully funded over an estimated five (5) year period and is contingent upon the delivery of key milestones throughout the period.

The contract is designed to provide US based manufacturing and clinical data to support a New Drug Application for laninamivir, to the US Food and Drug Administration.

Biota CEO, Peter Cook, commented, "The award provides visible recognition of the potential medical value of laninamivir to the world's major market. The BARDA contract will be a major contributor to a timely introduction of the product and will create the opportunity to significantly develop Biota's business in the USA."

Source:

Biota Holdings Limited

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Does pomegranate seed oil really help your heart? New research weighs the evidence

Eating habits directly influence vaginal microbiome, research finds

Can smoking while pregnant harm your child’s teeth? New research suggests yes

Is it time to rethink dairy? Here’s what 25 years of research reveals for women

Sapio Sciences and Ultima Genomics partner to advance multi-omics research

Research reveals Ghanaian children face high cancer risk from local fish

Snooze alarms steal hours of sleep each month, new research shows

New research reveals why fiber-rich diets fuel you better than refined foods

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.